Acquired Orphan Blood Disease Market reach a growth of US$ 21.5 Bn by 2032 – Persistence Market Research

Market Study on Acquired Orphan Blood Disease: North America to Account for Over One-third Global Market Share

New York, Oct. 20, 2022 (GLOBE NEWSWIRE) -- The global acquired orphan blood disease market is estimated to expand at a CAGR of 10.4% and value of US$ 21.5 Bn by 2032, up from US$ 8 Bn in 2022. North America is expected to remain the leading regional market through the forecast period of 2022 to 2032.

“Increasing Per Capita Income in Developing Nations”

At present, the per capita income of people living in developing countries is increasing at a noticeable speed that further bolsters their capacity to spend more on advanced healthcare solutions. The factor is likely to increase sales avenues in the global acquired orphan blood disease market.

The emergence of novel therapies is expected to open up new avenues for industry players. Moreover, in many emerging markets, for instance, India is also anticipated to create various new growth opportunities in the market while contributing to the demand avenues.

Request for sample copy of report:

“Increasing Prevalence of Blood-Related Diseases in North America”

North America is anticipated to hold a dominating position in the market owing to the rising count of blood-related diseases in the region. In addition, increased R&D investment in novel drugs and growing access to healthcare insurance facilities, especially in the U.S. are estimated to influence growth opportunities in the regional market.

After North America, Europe is also expected to grow at a noticeable speed in the years ahead due to the presence of well-structured and advanced healthcare solutions. East Asia and South Asia & Pacific regions are projected to grow at a rapid pace owing to increasing government initiatives for effective healthcare facilities and rising healthcare infrastructure. The presence of a larger patient population in the regions is expected to drive demand opportunities in the regional markets.

Get customized report as per requirement:

Acquired Orphan Blood Disease Industry Research by Category

By Therapy:

  • Recombinant Factor
  • Immunoglobulin Infusion Therapy
  • Activated Prothrombin Complex Concentrate
  • Thrombopoietin Receptor Agonists
  • Others

By Disease Indication:

  • Acquired Agranulocytosis
  • Acquired Hemophilia
  • Acquired Von Willebrand Syndrome
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Myelodysplastic Syndrome
  • Other

Get full access of report:

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy

Key Market Players

Key companies operating in this market are Alexion Pharmaceuticals, Inc., Amgen, Inc., Celgene Corporation, Eli Lilly and Company, Sanofi S.A., GlaxoSmithKline plc, and Cyclacel Pharmaceuticals, Inc. Some of the other companies operating in this market are Onconova Therapeutics, Inc., Incyte Corporation, and CTI BioPharma Corp.

Other Trending Reports:

About Persistence Market Research:

Business intelligence is the foundation of every business model employed by Persistence Market Research. Multi-dimensional sources are being put to work, which include big data, customer experience analytics, and real-time data collection. Thus, working on “micros” by Persistence Market Research helps companies overcome their “macro” business challenges.

Persistence Market Research is always way ahead of its time. In other words, it tables market solutions by stepping into the companies’/clients’ shoes much before they themselves have a sneak pick into the market. The pro-active approach followed by experts at Persistence Market Research helps companies/clients lay their hands on techno-commercial insights beforehand, so that the subsequent course of action could be simplified on their part.


Rajendra Singh

Persistence Market Research
U.S. Sales Office:
305 Broadway, 7th Floor
New York City, NY 10007
United States
USA - Canada Toll-Free: 800-961-0353